These results demonstrated that depletion of tumor-secreted RNase1 reduced M2-like TAM populations, enhanced cytotoxic CD8+ T cells, as well as the efficacy of αPD-1–based immunotherapy for HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.